Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ASTHENIC DISORDERS IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION: MANAGEMENT POTENTIAL OF MELDONIUM

https://doi.org/10.20996/1819-6446-2013-9-1-25-30

Full Text:

Abstract

Aim. To assess the effect of meldonium (in combination with antihypertensive therapy) on the severity of asthenic syndrome (AS) in elderly patients with arterial hypertension (HT).

Material and methods. Patients (n=180, >65 years old) with HT (grade 1–2) and secondary somatogenic AS (assessed by the MFI-20 scale). The patients were randomized into 3 groups according to the scheme of treatment. Group 1 — intermittent treatment with meldonium (500 mg once daily for 3 months followed by a break 3 months; 2 courses). Group 2 — continuous treatment with meldonium (500 mg once daily for 12 months). Group 3 — control (receive only antihypertensive drugs). Evaluation of AS was assessed by MFI-20 scales at baseline and at week 52 of treatment.

Results. AS signs attenuation was found in groups 1 and2. In group1 a number of patients with general asthenia decreased on 70.5% (p<0.05), with physical asthenia — on 47.7% (p<0.05), with reduced activity — on 33.3%, reduced motivation — on 25%. In group2 a number of patients with general asthenia decreased on 60% (p<0.05), physical asthenia — on 39.7%, reduced activity — on 79.9% (p<0.05), reduced motivation — on 12.2%, mental asthenia — on 77.7% (p<0.05). In group 3 no significant changes in these parameters were found. Moreover a number of patients with mental asthenia increased on 45.4% (p<0.05).

Conclusion. Meldonium included into antihypertensive therapy can reduce the symptoms of secondary somatogenic AS. More pronounced antiasthenic effect can be achieved with meldonium taking regime 500 mg daily continuously for 52 weeks.

About the Authors

M. E. Statsenko
Volgograd State Medical University
Russian Federation


S. V. Nedogoda
Volgograd State Medical University
Russian Federation


S. V. Turkina
Volgograd State Medical University
Russian Federation


I. A. Tyshchenko
Volgograd State Medical University
Russian Federation


L. V. Poletaeva
Volgograd State Medical University
Russian Federation


V. V. Tsoma
Volgograd State Medical University
Russian Federation


A. A. Ledyaeva
Volgograd State Medical University
Russian Federation


E. V. Chumachok
Volgograd State Medical University
Russian Federation


References

1. Avedisova A.S. Antiasthenic drugs as first-line therapy in asthenic disorders. Russkiy Meditsinskiy Zhurnal 2004; 12 (22): 1290–1292. Russian. (Аведисова А.С. Антиастенические препараты как терапия первого выбора при астенических расстройствах. Русский Медицинский Журнал 2004; 12 (22): 1290–2).

2. Carruthers B.M., Jain A.K., De Meirleir K.L., et al. Myalgic encephalomyalitis/chronic fatigue syndrome: Clinical working definition, diagnostic and treatment protocols. Journal of Chronic Fatigue Syndrome 2003;11 (1): 7–97.

3. Vereshhagin N.V., Morgunov V.A., Gulevskaja T.S. Brain pathology in atherosclerosis and arterial hypertensison. Moscow: Meditsina; 1997. Russian. (Верещагин Н.В., Моргунов В.А., Гулевская Т.С. Патология головного мозга при атеросклерозе и артериальной гипертонии. М.: Медицина; 1997).

4. Sidorov P.I., ed. Psihosomatic medicine. Moscow: MEDpress-inform; 2006. Russian (Сидоров П.И., редактор. Психосоматическая медицина. М.: МЕДпресс-информ; 2006).

5. Cockshell S. J., Mathias J. L Cognitive functioning in chronic fatigue syndrome: a meta-analysis. Psychological Medicine 2010; 40 (08):1253–1267.

6. Aleksandrovskij Ju.A. Borderline mental disorders. Textbook. 3rd edition. M.: Meditsina; 2000. Russian (Александровский Ю.А. Пограничные психические расстройства. Учебное пособие. 3-е издание. М.: Медицина; 2000).

7. Djukova G.M. Asthenia: criteria for diagnosis and treatment. Spravochnik Poliklinicheskogo Vracha 2007;(11):9–13. Russian (Дюкова Г.М. Астения: критерии диагностики и лечение. Справочник Поликлинического Врача 2007; (11): 9–13).

8. Kalvin'sh I.Ja. Mildronat – mechanism of action and prospects of its application. Riga: AO Grindeks; 2002. Russian (Калвиньш И.Я. Милдронат — механизм действия и перспективы его применения. Рига: АО Гриндекс; 2002).

9. Kuratsune H., Yamaguti K., Takahashi M., et al. Acylcarnitine deficiency in chronic fatigue syndrome. Clin Infect Dis 1994; 18(1): 62–7.

10. Reuter Stephanie E., Evans Allan M. Long-chain acylcarnitine deficiency in CFS. Potential involvement of altered carnitin. Journal of Internal Medicine 2011; 270 (1): 76–84.

11. Sjakste N., Gutcaits A., Kalvinsh I. Mildronate: an antiischemic drug for neurological indications. CNS Drug Rev 2005;11(2):151–168.

12. Damulin I.V., Koberskaja N.N., Antonenko L.M. Impact of mildronat on cognitive impairment at dyscirculatiry encephalopathy: clinical and electrophysiological study. Nevrologicheskiy Zhurnal 2006; (4):45– 50. Russian (Дамулин И.В., Коберская Н.Н., Антоненко Л.М. Влияние милдроната на когнитивные нарушения при дисциркуляторной энцефалопатии: клинико-электрофизиологическое исследование. Неврологический Журнал 2006; (4): 45–50).

13. Suslina Z.A., Fedorova T.N., Maksimova M.Ju. Antioxidant effect of mildronat and carnitine in treatment of patients with vascular disease of brain. Eksperimental'naya i Klinicheskaya Farmakologiya 2005; 66(3): 32–35. Russian (Суслина З.А., Федорова Т.Н., Максимова М.Ю. Антиоксидантное действие милдроната и карнитина при лечении больных с сосудистыми заболеваниями головного мозга. Экспериментальная и Клиническая Фармакология 2005; 66(3): 32–35).

14. Suslina Z.A., Maksimova M.Ju., Kistenev B.A., et al. Antioxidant therapy at patients with dyscirculatiry encephalopathy and diabetes mellitus type 2. Farmateka 2005; (12): 68–71. Russian (Суслина З.А., Максимова М.Ю., Кистенев Б.А., и др. Антиоксидантная терапия у больных дисциркуляторной энцефалопатией, отягощенной сахарным диабетом типа 2. Фарматека 2005; (12): 68–71).

15. Suslina Z.A., Maksimova M.Ju., Kistenev B.A., Fedorova T.N. Neuroprotection in ischemic stroke: efficacy оf mildronat. Farmateka 2005;(13): 99–104. Russian. (Суслина З.А., Максимова М.Ю., Кистенев Б.А., Федорова Т.Н. Нейропротекция при ишемическом инсульте: эффективность Милдроната. Фарматека 2005;(13): 99–104).

16. Maksimova M.Ju., Kistenev B.A., Domashenko M.A. et al. Clinical features and antioxidant effects of mildronat at in ischemic stroke. Rossiyskiy Kardiologicheskiy Zhurnal 2009;4 (78):55–63. Russian (Максимова М.Ю., Кистенев Б.А., Домашенко М.А. и др. Клиническая эффективность и антиоксидантная активность милдроната при ишемических инсультах. Российский Кардиологический Журнал 2009;4 (78):55–63).

17. Nedogoda S.V., Statsenko M.E., Turkina S.V. et al. Mildronate effects on cognitive function in elderly patients with arterial hypertension. Kardiovaskulyarnaya Terapiya i Profilaktika 2012; 11(5):33– 38. Russian (Недогода С.В., Стаценко М.Е., Туркина С.В. и др. Влияние терапии Милдронатом на когнитивные функции у больных пожилого возраста с артериальной гипертензией. Кардиоваскулярная Терапия и Профилактика 2012; 11(5):33–38).

18. Nedogoda S.V., Stacenko M.E. Therapist opportunities in cognitive function correction in arterial hypertension. Farmateka 2010;(10):21–27. Russian (Недогода С.В., Стаценко М.Е. Возможности терапевта в коррекции когнитивных нарушений при артериальной гипертензии. Фарматека 2010;(10):21–27).

19. Vizir V.A., Berezin A.E. Application prospects mildronata patients with heart failure, which developed as a result of coronary heart disease. Arterial'naya Gipertenziya 2012; 4(24): 49–54. Russian (Визир В.А., Березин А.Е. Перспективы применения милдроната у больных сердечной недостаточностью, развившейся вследствие ишемической болезни сердца. Артериальная Гипертензия 2012; 4(24): 49–54).

20. Statsenko M.E., Turkina S.V. Metabolic cardioprotection meldoniem in coronary heart disease: results and prospects. Lechashchiy Vrach 2012; (7): 62–65. Russian (Стаценко М.Е., Туркина С.В. Метаболическая кардиопротекция мельдонием при ишемической болезни сердца: итоги и перспективы. Лечащий Врач 2012; (7): 62–65).


For citation:


Statsenko M.E., Nedogoda S.V., Turkina S.V., Tyshchenko I.A., Poletaeva L.V., Tsoma V.V., Ledyaeva A.A., Chumachok E.V. ASTHENIC DISORDERS IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION: MANAGEMENT POTENTIAL OF MELDONIUM. Rational Pharmacotherapy in Cardiology. 2013;9(1):25-30. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-1-25-30

Views: 690


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)